News

Allurion to Report Second Quarter 2024 Financial Results on August 13, 2024

NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (NYSE: ALUR) (“Allurion” or the “Company”), a company dedicated to ending obesity, today announced that it will report financial results for the second quarter 2024 on Tuesday, August 13, 2024. Company management will host a conference call to discuss financial results and provide a business update on the same day at 8:30 AM ET. To access the conference call by telephone, please dial (888) 330-3417 (domestic) or +1 646 960 0804 (intern.

07/16/2024

Allurion Announces Launch of Offering of Common Stock and Warrants

NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (NYSE: ALUR) (“Allurion” or the “Company”), a company dedicated to ending obesity, today announced that it has launched an underwritten public offering of up to $20 million of its common stock, par value $0.0001 per share (the “Shares”), and warrants to purchase Shares (the “Warrants” and, together with the Shares, the “Securities”). Jefferies and TD Cowen are acting as joint book-running managers and representatives of the underwriter.

06/26/2024

Profitability

Dividends

Income Statement

Balance Sheet

Cash Flow Statement

Symbol Frequently Asked Questions

Is Allurion Technologies Inc. (ALUR) a buy, sell, or hold?

Allurion Technologies Inc. (ALUR) can hold. Click on Rating Page for detail.

What is Allurion Technologies Inc.'s stock price?

The price of Allurion Technologies Inc. (ALUR) is 0.8596 and it was updated on 2024-07-27 07:01:02.

Is Allurion Technologies Inc. (ALUR) overvalued or undervalued?

Currently Allurion Technologies Inc. (ALUR) is in undervalued.

News

From:

To:

News
Why Is Allurion (ALUR) Stock Up 140% Today? Among the medical companies seeing a big uptick today, Allurion (NYSE: ALUR ) could be among the most closely watched on Thursday. At the time of this writing, ALUR stock is up more than 140% as investors price in some very positive news from the small-cap weight loss-focused name. Thu, Jun. 20, 2024
Allurion Announces Publication of New Data Demonstrating Lean Mass Gains in Patients Experiencing 14% Weight Loss NATICK, Mass.--(BUSINESS WIRE)---- $ALUR #Allurion--Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced the publication of a study demonstrating an average lean mass gain of 5.6% in patients with an average weight loss of 14% at four months on the Allurion Program. Vital signs and physical activity were tracked in real-time with the Allurion App, Connected Scale, and Health Tracker, and follow-up was provided through the AI-powered Allurion Virtual Care Suite. In the st. Thu, Jun. 20, 2024
Allurion (ALUR) Unveils Positive Data for Its Balloon Therapy Allurion (ALUR) announces positive weight loss data for its gastric balloon technology. Fri, Jun. 14, 2024
Allurion Technologies, Inc. (ALUR) Loses -38.66% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner The heavy selling pressure might have exhausted for Allurion Technologies, Inc. (ALUR) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal. Tue, Jun. 11, 2024
Allurion Announces Three Scientific Presentations at the 40th Annual Meeting of the American Society for Metabolic and Bariatric Surgery NATICK, Mass.--(BUSINESS WIRE)---- $ALUR #Allurion--Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced three scientific presentations at the American Society for Metabolic and Bariatric Surgery Annual Meeting (ASMBS) taking place in San Diego, California, June 9-13, 2024. Data from a study of 121 patients across 11 obesity centers treated with two consecutive, four-month Allurion Balloons showed patients achieved 22.1% weight loss on average at one year. In comparison,. Tue, Jun. 11, 2024

Transcripts

Transcipts Data
Allurion Technologies Inc. (ALUR) on Q1 2024 Results - Earnings Call Transcript SA Transcripts Tue, May. 14, 2024
Allurion Technologies Inc. (ALUR) on Q4 2023 Results - Earnings Call Transcript SA Transcripts Thu, Mar. 21, 2024
Allurion Technologies Inc. (ALUR) on Q3 2023 Results - Earnings Call Transcript SA Transcripts Fri, Nov. 17, 2023

SEC Filings

SEC Filings
Allurion Technologies Inc. (ALUR) - SC 13D/A SEC Filings 07/02/2024
Allurion Technologies Inc. (ALUR) - EFFECT SEC Filings 07/01/2024
Allurion Technologies Inc. (ALUR) - 8-K - Current report SEC Filings 07/01/2024
Allurion Technologies Inc. (ALUR) - 424B3 SEC Filings 07/01/2024
Allurion Technologies Inc. (ALUR) - 424B4 SEC Filings 06/28/2024
Allurion Technologies Inc. (ALUR) - EFFECT SEC Filings 06/27/2024
Allurion Technologies Inc. (ALUR) - EFFECT SEC Filings 06/27/2024
Allurion Technologies Inc. (ALUR) - S-1 SEC Filings 06/26/2024
Allurion Technologies Inc. (ALUR) - 8-K - Current report SEC Filings 06/26/2024
Allurion Technologies Inc. (ALUR) - POS AM SEC Filings 06/21/2024
Allurion Technologies Inc. (ALUR) - 4 SEC Filings 06/05/2024
Allurion Technologies Inc. (ALUR) - 3 SEC Filings 06/05/2024
Allurion Technologies Inc. (ALUR) - S-1 SEC Filings 05/31/2024
Allurion Technologies Inc. (ALUR) - DRS SEC Filings 05/28/2024
Allurion Technologies Inc. (ALUR) - 8-K - Current report SEC Filings 05/14/2024
Allurion Technologies Inc. (ALUR) - 10-Q - Quarterly Report SEC Filings 05/14/2024
Allurion Technologies Inc. (ALUR) - 4 SEC Filings 05/07/2024
Allurion Technologies Inc. (ALUR) - 4 SEC Filings 05/06/2024
Allurion Technologies Inc. (ALUR) - 8-K - Current report SEC Filings 04/30/2024
Allurion Technologies Inc. (ALUR) - 10-K/A - Current report SEC Filings 04/29/2024
Allurion Technologies Inc. (ALUR) - SC 13D/A SEC Filings 04/17/2024
Allurion Technologies Inc. (ALUR) - 8-K - Current report SEC Filings 04/17/2024
Allurion Technologies Inc. (ALUR) - 10-K - Current report SEC Filings 03/26/2024
Allurion Technologies Inc. (ALUR) - 8-K - Current report SEC Filings 03/21/2024
Allurion Technologies Inc. (ALUR) - 424B3 SEC Filings 03/21/2024
Allurion Technologies Inc. (ALUR) - 4 SEC Filings 03/21/2024
Allurion Technologies Inc. (ALUR) - 3 SEC Filings 03/21/2024
Allurion Technologies Inc. (ALUR) - 8-K - Current report SEC Filings 03/15/2024
Allurion Technologies Inc. (ALUR) - SC 13G/A SEC Filings 02/14/2024
Allurion Technologies Inc. (ALUR) - 4 SEC Filings 02/12/2024
Allurion Technologies Inc. (ALUR) - 3 SEC Filings 02/01/2024
Allurion Technologies Inc. (ALUR) - 8-K - Current report SEC Filings 01/08/2024
Allurion Technologies Inc. (ALUR) - EFFECT SEC Filings 01/02/2024
Allurion Technologies Inc. (ALUR) - 424B3 SEC Filings 01/02/2024
Allurion Technologies Inc. (ALUR) - 8-K - Current report SEC Filings 12/29/2023
Allurion Technologies Inc. (ALUR) - 424B3 SEC Filings 12/29/2023
Allurion Technologies Inc. (ALUR) - CORRESP SEC Filings 12/27/2023
Allurion Technologies Inc. (ALUR) - SC 13G SEC Filings 12/26/2023
Allurion Technologies Inc. (ALUR) - D SEC Filings 12/22/2023
Allurion Technologies Inc. (ALUR) - UPLOAD SEC Filings 12/21/2023
Allurion Technologies Inc. (ALUR) - S-1 SEC Filings 12/19/2023
Allurion Technologies Inc. (ALUR) - 8-K - Current report SEC Filings 12/19/2023
Allurion Technologies Inc. (ALUR) - EFFECT SEC Filings 12/18/2023
Allurion Technologies Inc. (ALUR) - 8-K - Current report SEC Filings 12/15/2023
Allurion Technologies Inc. (ALUR) - 424B3 SEC Filings 12/15/2023
Allurion Technologies Inc. (ALUR) - CORRESP SEC Filings 12/14/2023
Allurion Technologies Inc. (ALUR) - 4 SEC Filings 12/14/2023
Allurion Technologies Inc. (ALUR) - S-1/A SEC Filings 12/08/2023
Allurion Technologies Inc. (ALUR) - S-1/A SEC Filings 11/30/2023
Allurion Technologies Inc. (ALUR) - CORRESP SEC Filings 11/29/2023
Allurion Technologies Inc. (ALUR) - 10-Q - Quarterly Report SEC Filings 11/14/2023
Allurion Technologies Inc. (ALUR) - 8-K - Current report SEC Filings 11/13/2023
Allurion Technologies Inc. (ALUR) - UPLOAD SEC Filings 11/03/2023
Allurion Technologies Inc. (ALUR) - 4 SEC Filings 10/25/2023
Allurion Technologies Inc. (ALUR) - S-8 SEC Filings 10/20/2023
Allurion Technologies Inc. (ALUR) - S-1/A SEC Filings 10/20/2023
Allurion Technologies Inc. (ALUR) - CORRESP SEC Filings 10/20/2023
Allurion Technologies Inc. (ALUR) - 10-Q - Quarterly Report SEC Filings 10/20/2023
Allurion Technologies Inc. (ALUR) - UPLOAD SEC Filings 09/29/2023
Allurion Technologies Inc. (ALUR) - S-1 SEC Filings 09/18/2023
Allurion Technologies Inc. (ALUR) - 8-K/A - Current report SEC Filings 08/14/2023
Allurion Technologies Inc. (ALUR) - SC 13D SEC Filings 08/11/2023
Allurion Technologies Inc. (ALUR) - 8-K - Current report SEC Filings 08/07/2023
Allurion Technologies Inc. (ALUR) - CERT SEC Filings 08/01/2023
Allurion Technologies Inc. (ALUR) - 8-K - Current report SEC Filings 08/01/2023
Allurion Technologies Inc. (ALUR) - 8-A12B SEC Filings 08/01/2023
Allurion Technologies Inc. (ALUR) - 3 SEC Filings 08/01/2023
Allurion Technologies Inc. (ALUR) - 425 SEC Filings 07/26/2023
Allurion Technologies Inc. (ALUR) - 424B3 SEC Filings 07/26/2023
Allurion Technologies Inc. (ALUR) - 425 SEC Filings 07/25/2023
Allurion Technologies Inc. (ALUR) - 424B3 SEC Filings 07/25/2023
Allurion Technologies Inc. (ALUR) - 424B3 SEC Filings 07/24/2023
Allurion Technologies Inc. (ALUR) - EFFECT SEC Filings 07/10/2023
Allurion Technologies Inc. (ALUR) - S-4/A SEC Filings 07/07/2023
Allurion Technologies Inc. (ALUR) - CORRESP SEC Filings 07/07/2023
Allurion Technologies Inc. (ALUR) - 424B3 SEC Filings 07/07/2023
Allurion Technologies Inc. (ALUR) - S-4/A SEC Filings 07/06/2023
Allurion Technologies Inc. (ALUR) - CORRESP SEC Filings 07/06/2023
Allurion Technologies Inc. (ALUR) - UPLOAD SEC Filings 07/03/2023
Allurion Technologies Inc. (ALUR) - S-4/A SEC Filings 06/27/2023
Allurion Technologies Inc. (ALUR) - CORRESP SEC Filings 06/27/2023
Allurion Technologies Inc. (ALUR) - UPLOAD SEC Filings 06/22/2023
Allurion Technologies Inc. (ALUR) - S-4/A SEC Filings 06/14/2023
Allurion Technologies Inc. (ALUR) - S-4/A SEC Filings 06/13/2023
Allurion Technologies Inc. (ALUR) - CORRESP SEC Filings 06/13/2023
Allurion Technologies Inc. (ALUR) - 425 SEC Filings 06/09/2023
Allurion Technologies Inc. (ALUR) - UPLOAD SEC Filings 06/01/2023
Allurion Technologies Inc. (ALUR) - S-4 SEC Filings 05/12/2023
Allurion Technologies Inc. (ALUR) - CORRESP SEC Filings 05/12/2023
Allurion Technologies Inc. (ALUR) - 425 SEC Filings 05/02/2023
Allurion Technologies Inc. (ALUR) - UPLOAD SEC Filings 03/13/2023
Allurion Technologies Inc. (ALUR) - DRS SEC Filings 02/14/2023
Allurion Technologies Inc. (ALUR) - 425 SEC Filings 02/10/2023
Allurion Technologies Inc. (ALUR) - 425 SEC Filings 02/09/2023

Press Releases

StockPrice Release
Allurion to report second quarter 2024 financial results on august 13, 2024 07/16/2024
Allurion announces launch of offering of common stock and warrants 06/26/2024
Allurion announces publication of new data demonstrating lean mass gains in patients experiencing 14% weight loss 06/20/2024
Allurion announces three scientific presentations at the 40th annual meeting of the american society for metabolic and bariatric surgery 06/11/2024
Allurion announces the appointment of ojas a. buch as chief operating officer 06/05/2024
Allurion announces expansion of ai weight loss coach to support patients on glp-1s 05/30/2024
Allurion to participate in two upcoming investor conferences in june 2024 05/29/2024
Allurion announces three scientific presentations at the european congress on obesity, including study on lean mass preservation for sustainable, healthy weight loss 05/15/2024
Allurion reports first quarter 2024 financial results and provides business update 05/14/2024
Allurion announces three scientific presentations at ifso-european chapter 2024, including first-ever 3-year weight maintenance survey 05/02/2024
Allurion announces preliminary first quarter 2024 results 04/30/2024
Allurion closes $48 million convertible senior secured note financing with rtw investments 04/17/2024
Allurion expands virtual care suite to the united states 04/04/2024
Allurion reports fourth quarter and full year 2023 financial results and reiterates 2024 guidance 03/21/2024
Milena alberti-perez joins allurion board of directors as audit committee chair 03/12/2024
Brendan gibbons appointed chief legal officer at allurion technologies 01/29/2024
Somerset nhs foundation trust treats first patients with allurion balloon for pre-surgical weight loss 01/23/2024
World first : somerset nhs foundation trust treats first patients with allurion balloon for pre-surgical weight loss 01/23/2024
Allurion's virtual care suite digital platform accelerates commercial expansion with new strategic partnerships 01/17/2024
Allurion announces publication of randomized, double-blind study demonstrating significant improvement in obesity-related co-morbidities 01/11/2024
New research highlights the positive impact of glp-1s and other anti-obesity medications on the allurion program 01/05/2024
Allurion's digital platform gains traction with expanded strategic partnership 01/02/2024
Allurion to report third quarter 2023 financial results on november 13, 2023 11/06/2023
Allurion completes enrollment in pivotal audacity trial for the allurion balloon 10/11/2023
Allurion featured at the 2023 international bariatric club oxford university world congress 09/18/2023
Allurion introduces coach iris: a 24/7 generative ai-powered weight loss coach 08/29/2023
Allurion announces acceptance of nine scientific presentations at ifso 2023 world congress 08/28/2023

More Headlines

News
Allurion Announces the Appointment of Ojas A. Buch as Chief Operating Officer NATICK, Mass.--(BUSINESS WIRE)---- $ALUR #Allurion--Allurion Technologies, Inc. (NYSE:ALUR), a company dedicated to ending obesity, today announced the appointment of Ojas A. Buch as its new Chief Operating Officer. Effective June 3, 2024, Ojas assumed the role of Chief Operating Officer and will lead the company's Research and Development, Manufacturing and Operations, Quality and Regulatory, and Business Development and Innovation functions. He will also play a crucial role in commercial functions while working. 06/05/2024
Allurion Announces Expansion of AI Weight Loss Coach to Support Patients on GLP-1s NATICK, Mass.--(BUSINESS WIRE)---- $ALUR #Allurion--Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced the expansion of its Artificial Intelligence (AI)-powered weight loss coach, Coach Iris, to support patients prescribed GLP-1s and other anti-obesity medications and the first commercial agreements for its Virtual Care Suite (VCS) in the United States. With this update to Coach Iris, patients now have access to 24/7 personalized coaching and guidance specific to GLP-1. 05/30/2024
Allurion to Participate in Two Upcoming Investor Conferences in June 2024 NATICK, Mass.--(BUSINESS WIRE)--Allurion to Participate in Two Upcoming Investor Conferences in June 2024. 05/29/2024
Allurion Announces Three Scientific Presentations at the European Congress on Obesity, Including Study on Lean Mass Preservation for Sustainable, Healthy Weight Loss NATICK, Mass.--(BUSINESS WIRE)---- $ALUR #Allurion--Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced three scientific presentations at the 31st European Congress on Obesity (ECO) held in Venice, Italy, on 12-15 May, 2024. Presentations include data from a study of 712 patients treated with the Allurion Program, which is anchored by the Allurion Balloon and enhanced by the Virtual Care Suite featuring Allurion's proprietary behavior change program. This study was cond. 05/15/2024
Allurion Reports First Quarter 2024 Financial Results and Provides Business Update NATICK, Mass.--(BUSINESS WIRE)--Allurion Reports First Quarter 2024 Financial Results and Provides Business Update. 05/14/2024
Allurion Announces Three Scientific Presentations at IFSO-European Chapter 2024, Including First-Ever 3-Year Weight Maintenance Survey NATICK, Mass.--(BUSINESS WIRE)---- $ALUR #Allurion--Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced three oral scientific presentations at the 12th Congress of the International Federation for the Surgery of Obesity and Metabolic Disorders – European Chapter (IFSO-EC) held in Vienna, Austria on 2-4 May 2024. Presentations include data from a survey of 133 patients across seven international obesity centers that shows patients on the Allurion Program lost just over 1. 05/02/2024
Allurion Announces Preliminary First Quarter 2024 Results NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced preliminary, unaudited results for the first quarter 2024. Management expects preliminary unaudited results for the period as follows: Revenue in the range of $9.2 million to $9.3 million, reflecting growth of between 12%-13% over the fourth quarter of 2023 Procedural volume growth, as estimated by new app users, reflecting 22% growth ove. 04/30/2024
Allurion Closes $48 Million Convertible Senior Secured Note Financing with RTW Investments NATICK, Mass.--(BUSINESS WIRE)--Allurion Closes $48 Million Convertible Senior Secured Note Financing with RTW Investments. 04/17/2024
Why Is Allurion (ALUR) Stock Up 65% Today? Little-known medical device firm Allurion (NYSE: ALUR ) — which is focused on ending obesity via its swallowable and “procedure-less” intragastric balloon — saw its shares skyrocket on Thursday. Earlier this morning, management announced the commercial availability of its comprehensive Virtual Care Suite (VCS) in the U.S. ALUR stock likely benefited from rising interest in anti-obesity treatments. 04/04/2024
Allurion Expands Virtual Care Suite to the United States NATICK, Mass.--(BUSINESS WIRE)---- $ALUR #Allurion--Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced the commercial availability of its comprehensive Virtual Care Suite (VCS) in the United States. Already in use by thousands of providers in over 50 countries, the VCS is a dynamic weight-loss management suite powered by artificial intelligence (AI) featuring remote patient monitoring, telehealth and care team collaboration all under the one digital umbrella, designed. 04/04/2024
Allurion Technologies Inc. (ALUR) Q4 2023 Earnings Call Transcript Allurion Technologies Inc. (ALUR) Q4 2023 Earnings Call Transcript 03/21/2024
Allurion Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 Guidance NATICK, Mass.--(BUSINESS WIRE)--Allurion Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 Guidance. 03/21/2024
Milena Alberti-Perez Joins Allurion Board of Directors as Audit Committee Chair NATICK, Mass.--(BUSINESS WIRE)---- $ALUR #Allurion--Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced the appointment of its newest board member and Audit Committee Chair, Milena Alberti-Perez, effective as of March 11, 2024. "Milena joins the Allurion board during an exciting time in the company's history and is a proven and dynamic leader, with deep experience as an operator and board member," said Dr. Shantanu Gaur, Allurion Founder and CEO. "Her perspective and gu. 03/12/2024
Brendan Gibbons Appointed Chief Legal Officer at Allurion Technologies NATICK, Mass.--(BUSINESS WIRE)---- $ALUR #Allurion--Allurion Technologies, Inc. (NYSE:ALUR), a company dedicated to ending obesity, today announced the appointment of Brendan Gibbons as its new Chief Legal Officer and corporate secretary. Brendan joins Allurion with nearly 20 years' experience as a chief legal and compliance officer at three separate public companies. Most recently, Brendan served as Executive Vice President and Chief Legal Officer at Acushnet Company, the parent company of Titleist and other golf. 01/29/2024
Somerset NHS Foundation Trust Treats First Patients with Allurion Balloon for Pre-Surgical Weight Loss NATICK, Mass.--(BUSINESS WIRE)---- $ALUR #Allurion--Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced that the Somerset NHS Foundation Trust (FT) is the first NHS trust in the United Kingdom, and the first non-private sector organisation in the world, to introduce the Allurion Gastric Balloon - the world's only swallowable gastric balloon that requires no surgery, no endoscopy and no anaesthesia1. Once swallowed, the balloon is filled and remains in the stomach for ap. 01/23/2024
World first : Somerset NHS Foundation Trust Treats First Patients with Allurion Balloon for Pre-Surgical Weight Loss NATICK, Mass.--(BUSINESS WIRE)---- $ALUR #Allurion--Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced that the Somerset NHS Foundation Trust (FT) is the first NHS trust in the United Kingdom, and the first non-private sector organisation in the world, to introduce the Allurion Gastric Balloon - the world's only swallowable gastric balloon that requires no surgery, no endoscopy and no anaesthesia1. Once swallowed, the balloon is filled and remains in the stomach for ap. 01/23/2024
Allurion's Virtual Care Suite Digital Platform Accelerates Commercial Expansion With New Strategic Partnerships NATICK, Mass.--(BUSINESS WIRE)---- $ALUR #Allurion--Allurion Technologies, Inc. (NYSE:ALUR), a company dedicated to ending obesity, today announced further expansion of its Virtual Care Suite (VCS) digital platform with new commercial agreements signed with Lazeo, France's largest aesthetic and weight loss clinic chain, and Transform, UK's largest aesthetic and weight loss clinic chain. After recently expanding its commercial agreement with Weight Doctors®—Germany's leading group of private clinics and centers for. 01/17/2024
Allurion Announces Publication of Randomized, Double-Blind Study Demonstrating Significant Improvement in Obesity-Related Co-Morbidities NATICK, Mass.--(BUSINESS WIRE)---- $ALUR #Allurion--Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced the publication of a randomized, double-blind study in Obesity Surgery that demonstrated significant reductions in type 2 diabetes, hypertension, and obstructive sleep apnea in just 4 months on the Allurion Program. These results improved with the addition of oral GLP-1 agonist semaglutide. In the study, 115 patients were randomized to either the Allurion Program with. 01/11/2024
New research highlights the positive impact of GLP-1s and other anti-obesity medications on the Allurion Program NATICK, Mass.--(BUSINESS WIRE)---- $ALUR #Allurion--Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced results of research that highlighted the positive impact of the growing interest in anti-obesity medications on Allurion Program awareness and uptake. The global market for anti-obesity medications – specifically of GLP-1s (glucagon-like peptide-1 receptor agonists) – is expected to reach $100 billion by 2030.1 Research has shown these products have significantly alte. 01/05/2024
Allurion's Digital Platform Gains Traction with Expanded Strategic Partnership NATICK, Mass.--(BUSINESS WIRE)---- $ALUR #Allurion--Allurion Technologies, Inc. (NYSE:ALUR), a company dedicated to ending obesity, today announced an expanded commercial agreement with Weight Doctors®—Germany's leading group of private clinics and centers for weight loss—and the hiring of Brian Conyer to lead commercialization of Allurion's rapidly growing digital assets. After a successful 2023 in which it managed over 2,000 patients on Allurion's Virtual Care Suite (VCS) digital platform, Weight Doctors has sig. 01/02/2024
Allurion Technologies Inc. (ALUR) Q3 2023 Earnings Call Transcript Allurion Technologies Inc. (NYSE:ALUR ) Q3 2023 Results Conference Call November 13, 2023 8:30 AM ET Company Participants Mike Cavanaugh - ICR of Westwicke Shantanu Gaur - Founder and Chief Executive Officer Chris Geberth - Chief Financial Officer Conference Call Participants Anthony Petrone - Mizuho Ross Osborn - Cantor Fitzgerald Ryan Zimmerman - BTIG Chris Pasquale - Nephron Research Operator Hello, and welcome to the Allurion Third Quarter Earnings Call. All lines have been placed on mute to prevent any background noise. 11/17/2023
Allurion to Report Third Quarter 2023 Financial Results on November 13, 2023 NATICK, Mass.--(BUSINESS WIRE)--Allurion to Report Third Quarter 2023 Financial Results on November 13, 2023. 11/06/2023
Allurion Completes Enrollment in Pivotal AUDACITY Trial for the Allurion Balloon NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced the completion of patient enrollment in its AUDACITY trial. AUDACITY is a randomized, pivotal controlled trial designed to support U.S. Food and Drug Administration (FDA) approval of the Allurion Balloon. The trial enrolled 550 patients at 17 sites and completed enrollment two months ahead of schedule. “I believe the brisk enrollment in the AUDACITY trial reflects the. 10/11/2023

Unlock

ALUR Ratings Summary

ALUR Quant Ranking

Is Allurion Technologies Inc. (ALUR) a buy, sell, or hold?

What is Allurion Technologies Inc.'s stock price?

Is Allurion Technologies Inc. (ALUR) overvalued or undervalued?

Allurion Announces the Appointment of Ojas A. Buch as Chief Operating Officer

Allurion Announces Expansion of AI Weight Loss Coach to Support Patients on GLP-1s

Allurion to Participate in Two Upcoming Investor Conferences in June 2024

Allurion Announces Three Scientific Presentations at the European Congress on Obesity, Including Study on Lean Mass Preservation for Sustainable, Healthy Weight Loss

Allurion Reports First Quarter 2024 Financial Results and Provides Business Update

Allurion Announces Three Scientific Presentations at IFSO-European Chapter 2024, Including First-Ever 3-Year Weight Maintenance Survey

Allurion Announces Preliminary First Quarter 2024 Results

Allurion Closes $48 Million Convertible Senior Secured Note Financing with RTW Investments

Why Is Allurion (ALUR) Stock Up 65% Today?

Allurion Expands Virtual Care Suite to the United States

Allurion Technologies Inc. (ALUR) Q4 2023 Earnings Call Transcript

Allurion Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 Guidance

Milena Alberti-Perez Joins Allurion Board of Directors as Audit Committee Chair

Brendan Gibbons Appointed Chief Legal Officer at Allurion Technologies

Somerset NHS Foundation Trust Treats First Patients with Allurion Balloon for Pre-Surgical Weight Loss

World first : Somerset NHS Foundation Trust Treats First Patients with Allurion Balloon for Pre-Surgical Weight Loss